US Stock MarketDetailed Quotes
SLN Silence Therapeutics
- 7.700
- +0.770+11.11%
Trading Nov 21 14:16 ET
363.55MMarket Cap-4526P/E (TTM)
7.700High6.430Low663.55KVolume6.870Open6.930Pre Close4.72MTurnover2.75%Turnover RatioLossP/E (Static)47.21MShares27.72052wk High3.04P/B185.87MFloat Cap5.81052wk Low--Dividend TTM24.14MShs Float35.000Historical High--Div YieldTTM18.33%Amplitude4.545Historical Low7.114Avg Price1Lot Size
About Silence Therapeutics Company
Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.
Company Profile
SymbolSLN
Company NameSilence Therapeutics
Founded1994
CEOMr. Craig A. Tooman
MarketNASDAQ
Employees109
Securities TypeDR
ADS Ratio1.0 : 3.0
Fiscal Year Ends12-31
Address72 Hammersmith Road
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeW14 8TH
Phone44-20-3457-6900
Company Executives
- Name
- Position
- Salary
- Craig A. Tooman
- President, Chief Executive Officer and Director
- 7.30M
- Rhonda L. Hellums
- Chief Financial Officer
- 2.50M
- Iain Gladstone Ross
- Non-Executive Chairman of the Board
- 402.00K
- Dr. Michael Harvey Davidson, M.D.
- Independent Director
- 178.00K
- David Jakob Lemus
- Independent Director
- 184.00K
- Alistair William Gray
- Senior Independent Director
- 193.00K
- James Lawrence Ede-Golightly
- Independent Director
- 182.00K
- Dr. Steven Joseph Romano, M.D.
- Head of Research and Development
- 1.73M
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data